EGFR is a therapeutic target in basal-like breast cancer, ErbB-2 is a target in the ErbB-2 overexpressing breast cancers, and ER-α is a target to hormone therapy in luminal breast cancers. This evidence concerns the gene EGFR and breast carcinoma.